Currently, there are 100.11M common shares owned by the public and among those 99.72M shares have been available to trade.
The company’s stock has a 5-day price change of -23.66% and 263.10% over the past three months. VKTX shares are trading 260.56% year to date (YTD), with the 12-month market performance up to 548.31% higher. It has a 12-month low price of $8.28 and touched a high of $99.41 over the same period. VKTX has an average intraday trading volume of 5.81 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.04%, 83.30%, and 229.93% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 69.20% of the company’s 100.11M shares outstanding.
It has a market capitalization of $7.34B and a beta (3y monthly) value of 1.06. The earnings-per-share (ttm) stands at -$0.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.20% over the week and 12.75% over the month.
Analysts forecast that Viking Therapeutics Inc (VKTX) will achieve an EPS of -$0.28 for the current quarter, -$0.28 for the next quarter and -$1.46 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.32 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.25 a year ago. Earnings per share for the fiscal year are expected to decrease by -22.00%, and -30.50% over the next financial year. EPS should grow at an annualized rate of 40.00% over the next five years, compared to -18.89% over the past 5-year period.
Looking at the support for the VKTX, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on March 07, 2024, with the firm’s price target at $110. Oppenheimer coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on February 28, 2024 offered a Outperform rating with a price target of $116. ROTH MKM was of a view on May 31, 2023 that the stock is Buy, while Maxim Group gave the stock Buy rating on March 28, 2023, issuing a price target of $15- $25. Stifel on their part issued Buy rating on March 17, 2023.
